We would love for you to become a part of our community. Join our Discord to connect with us and other members!

Ticker
IBAB.BR

Price
13.30
Stock movement up
+0.20 (1.53%)
Company name
Ion Beam Applications SA
Exchange
(BR
,
Currency
EUR
)
Sector
Healthcare >
Medical Devices
Markedsverdi
388.11M
Ent verdi
833.80M
Pris/omsetning
0.61
Pris/bok
4.30
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-8.99%
Etterfølgende P/E
-
Fremtidig P/E
12.67
PEG
-
EPS-vekst
15.97%
1 års avkastning
15.25%
3 års avkastning
-3.54%
5 års avkastning
6.41%
10 års avkastning
-3.28%
Sist oppdatert: 2024-12-21

UTBYTTE

IBAB.BR betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA29.93
EV i forhold til EBITDA64.30

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning0.61
Pris til bok4.30
EV i forhold til salg1.31

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall29.18M
EPS (TTM)-0.67
FCF per aksje (TTM)-3.68

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)635.17M
Bruttofortjeneste (TTM)204.27M
Driftsinntekter (TTM)3.46M
Netto inntekt (TTM)-19.41M
EPS (TTM)-0.67
EPS (1 år fremover)1.05

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)32.16%
Driftsmargin (TTM)0.54%
Fortjenestemargin (TTM)-3.06%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter60.19M
Netto fordringer165.72M
Samlede omløpsmidler449.19M
Goodwill11.45M
Immaterielle eiendeler14.12M
Eiendom, anlegg og utstyr0.00
Sum eiendeler596.16M
Leverandørgjeld66.24M
Kortsiktig/nåværende langsiktig gjeld59.98M
Sum kortsiktig gjeld467.11M
Sum gjeld505.87M
Aksjonærenes egenkapital90.28M
Netto varige driftsmidler0.00

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-91.43M
Kapitalutgifter (TTM)15.86M
Fri kontantstrøm (TTM)-107.29M
Utbetalt utbytte (TTM)9.64M

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-21.50%
Avkastning på eiendeler-3.26%
Avkastning på investert kapital-16.02%
Kontantavkastning på investert kapital-88.53%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning13.08
Daglig høy13.38
Daglig lav13.00
Daglig volum37K
Tidenes høyeste64.49
1 år analytikerestimat17.97
Beta0.99
EPS (TTM)-0.67
Utbytte per aksje-
Ex-div dato19 Jun 2024
Neste dato for resultatpresentasjon19 Mar 2025

Nedsidepotensial

Loading...
Nedsidepotensial-data
IBAB.BRS&P500
Nåværende prisfall fra toppnotering-79.38%-2.74%
Høyeste prisfall-95.97%-56.47%
Dato for høyeste fall28 Mar 20039 Mar 2009
Gj.snittlig fall fra topp-72.91%-11.13%
Gj.snittlig tid til ny topp322 days12 days
Maks tid til ny topp6557 days1805 days
SELSKAPSOPPLYSNINGER
IBAB.BR (Ion Beam Applications SA) company logo
Markedsverdi
388.11M
Markedsverdi kategori
Small-cap
Beskrivelse
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Ansatte
1943
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
Belgium
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
NOTICE OF A GENERAL MEETING OF IBA SA 7 January 2025 at 10 a.m. Dear Shareholder, We have the honour of convening you to a General Meeting of IBA (the "GM") at the Company's [registered office] on 7 J...
6. desember 2024
Louvain-la-Neuve, Belgium, 5 December 2024 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, announces today an initiative aimed at perpetuating the entrepreneuria...
5. desember 2024
Louvain-la-Neuve, Belgium, 21 November 2024 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the third quarter ending 30 ...
21. november 2024
Fourth agreement secured by IBA Industrial Solutions in past six weeks Louvain-la-Neuve, Belgium, November 06, 2024 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technolo...
6. november 2024
A EUR 16 million Initiative to Establish Strategic EU Autonomy in Alpha Therapies for Cancer Louvain-la-Neuve, Belgium, October 3, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader i...
3. oktober 2024
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, October 1st, 2024 06:00 Summary of the notification IBA (Ion Beam Applications), the w...
1. oktober 2024
Louvain-la-Neuve, Belgium, September 11, 2024 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, is pleased to share the below press release from its joint venture...
11. september 2024
GROUP REVENUES UP 21.9% ACCELERATED BACKLOG CONVERSION IN PROTON THERAPY AND OTHER ACCELERATORS STRONG GROSS MARGIN IMPROVEMENT AND BREAKEVEN REBIT Louvain-la-Neuve, Belgium, 29 August 2024 - IBA (Ion...
29. august 2024
Agreement further strengthens the long-term relationship between IBA and the University of Pennsylvania Louvain-La-Neuve, Belgium, August 27, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the wor...
27. august 2024
HY24 results webcast to take place on Thursday, 29 August 2024 at 3pm CEST Louvain-la-Neuve, Belgium, 1 August 2024 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerat...
1. august 2024
Neste side